SCHEMBL6750266

SCHEMBL6750266

CC(C)[N+](OCCc1ccncc1)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.42
LTA4H P09960 1/20 0.40
CYP19A1 P11511 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
HRH1 P35367 2/20 0.37
ACACB O00763 1/20 0.36
ABCB1 P08183 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14499016 0.76 L3MBTL1 (0.45) LOXL2LTA4HCYP19A1ALDH1A1KDM4E
SCHEMBL6753828 0.74 TSHR (0.50) LOXL2ALDH1A1POLBMAPT
SCHEMBL5402692 0.73 LOXL2 (0.50) LOXL2LTA4HALDH1A1KDM4ECYP1A2
SCHEMBL6007690 0.72 LOXL2 (0.54) LOXL2LTA4HALDH1A1KDM4ECYP1A2
SCHEMBL6750267 0.72 LOXL2 (0.41) LOXL2LTA4HCYP19A1ALDH1A1KDM4E
SCHEMBL22268002 0.72 CYP19A1 (0.53) LOXL2LTA4HCYP19A1ALDH1A1KDM4E
SCHEMBL2149218 0.69 LOXL2 (0.46) LOXL2LTA4HALDH1A1KDM4ECYP1A2
SCHEMBL12530528 0.69 TSHR (0.50) LOXL2CYP19A1ALDH1A1KDM4ECYP1A2
SCHEMBL2075759 0.69 KMT2A (0.45) LOXL2LTA4HALDH1A1KDM4ECYP1A2
SCHEMBL3169969 0.69 LOXL2 (0.50) LOXL2CYP19A1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof CHATTOPADHYAYA JYOTI (SE) 2004-07-22 US claimed
EP-1332150-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF Chattopadhyaya, Jyoti (SE) 2003-08-06 EP claimed
WO-2002038578-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF CHATTOPADHYAYA JYOTI (SE) 2002-05-16 WO claimed
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 US claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof RNASEH1, RNASEL, NSUN2 LOXL2 1101/4885LTA4H 519/4885CYP19A1 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.